汇宇制药(688553.SH)：HYP-6589片联合用药获得药物临床试验申请受理

Core Viewpoint - The company Huayu Pharmaceutical (688553.SH) announced that its wholly-owned subsidiary Sichuan Huayu Haiyue Pharmaceutical Technology Co., Ltd. received a notice from the National Medical Products Administration for the clinical trial application of HYP-6589 tablets in combination with Osimertinib for the treatment of advanced non-small cell lung cancer with target-driven gene positivity [1] Group 1 - HYP-6589 tablets are a highly selective SOS1 small molecule inhibitor developed by the company's subsidiary, classified as a Class 1 innovative chemical drug [1] - The drug has been approved for clinical research in China for monotherapy in advanced solid tumors [1] - The new application for clinical trials in combination with Osimertinib for advanced non-small cell lung cancer has been accepted, with no similar products approved for marketing domestically or internationally as of the announcement date [1]